Age yrs | 69.7±13.8 |
Females | 99 (34.3) |
PSI score | 112.9±25.7 |
Class IV | 198 (68.5) |
Class V | 52 (18.0) |
APACHE II score | 13.8±4.6 |
Comorbidity | 180 (62.3) |
Congestive heart failure | 36 (12.5) |
Neoplasm | 65 (22.5) |
Liver disease | 3.0 (1.0) |
Cerebrovascular disease | 25 (8.7) |
Chronic renal disease | 27 (9.3) |
COPD | 88 (30.4) |
Clinical features | |
Temperature °C | 38.5±1.2 |
Respiratory rate breaths·min−1 | 26.7±8.7 |
Laboratory data | |
CRP mg·L−1 | 174 (147–390) |
White blood cell count 109·L−1 | 16.5±9.2 |
Antibiotic therapy | |
β-lactam | 232 (80.3) |
Amoxicillin ± clavulanic acid | 169 (58.5) |
Cephalosporin (2nd or 3rd generation) | 60 (20.7) |
Cephtriaxone | 47 (16.2) |
Cephtazidime | 12 (4.2) |
Cephotaxime | 1 (0.3) |
Penicillin | 3 (1.0) |
β-lactam/macrolide combination | 47 (16.3) |
Amoxicillin ± clavulanic acid and macrolide | 32 (11.1) |
Cephalosporin (2nd or 3rd generation) and macrolide | 14 (4.8) |
Cephtriaxone and macrolide | 11 (3.8) |
Cephtazidime and macrolide | 2 (0.7) |
Other# | 10 (3.5) |
Outcome | |
ICU admissions during hospitalisation | 9 (3.1) |
28-day mortality | 20 (6.9) |
Data are presented as mean±sd, n (%) or median (interquartile range). PSI: Pneunomia Severity Index; APACHE: Acute Physiology and Chronic Health Evaluation; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; ICU: intensive care unit. #: other antibiotics include: cotrimoxazole (n = 2; 0.7%); β-lactam and ciprofloxacin (n = 2; 0.7%); doxycyclin (n = 2; 0.7%); erytromycin and rifampicin (n = 1; 0.3%); levofloxacin (n = 1; 0.3%); and erythromycin (n = 2; 0.6%).